ISIN
FR0012127173
Ticker
OSE
Sector
Sub-Industry
Country
France
Year Founded
2016
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics has 70 employees and is listed on Euronext Paris.
70
Worldwide
Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
---|---|---|---|
Assets | N/A | 96,973,000.00 | 101,876,000.00 |
Noncurrent Assets | N/A | 57,141,000.00 | 57,670,000.00 |
Property Plant And Equipment | N/A | 947,000.00 | 926,000.00 |
Intangible Assets Other Than Goodwill | N/A | 52,600,000.00 | 51,122,000.00 |
Deferred Tax Assets | N/A | 165,000.00 | 173,000.00 |
Current Assets | N/A | 39,832,000.00 | 44,206,000.00 |
Current Trade Receivables | N/A | 1,074,000.00 | 772,000.00 |
Cash and cash equivalents | 25,842,000.00 | 29,368,000.00 | 33,579,000.00 |
Shortterm Deposits Classified As Cash Equivalents | N/A | N/A | 1,000.00 |
Other Current Assets | N/A | 9,390,000.00 | 9,854,000.00 |
Equity And Liabilities | N/A | 96,973,000.00 | 101,876,000.00 |
Equity | 58,536,000.00 | 61,364,000.00 | 47,890,000.00 |
Issued Capital | N/A | 3,597,000.00 | 3,705,000.00 |
Share Premium | N/A | 65,449,000.00 | 65,605,000.00 |
Treasury Shares | N/A | 93,000.00 | 160,000.00 |
Noncurrent Liabilities | N/A | 21,481,000.00 | 37,224,000.00 |
Noncurrent Provisions | N/A | 531,000.00 | 710,000.00 |
Deferred Tax Liabilities | N/A | 2,080,000.00 | 1,748,000.00 |
Longterm Borrowings | N/A | 16,552,000.00 | 30,801,000.00 |
Current Liabilities | N/A | 14,128,000.00 | 16,761,000.00 |
Trade And Other Current Payables To Trade Suppliers | N/A | 10,286,000.00 | 9,607,000.00 |
Current Payables On Social Security And Taxes Other Than Income Tax | N/A | 2,108,000.00 | 3,724,000.00 |
Current Tax Liabilities Current | N/A | 2,000.00 | 14,000.00 |
Other Current Liabilities | N/A | 1,088,000.00 | 1,050,000.00 |
Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 50,000.00 | 1,611,000.00 |
Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
---|---|---|
Revenue | 10,432,000.00 | 26,306,000.00 |
Other Revenue | 13,000.00 | 0.00 |
Revenue From Contracts With Customers | 10,418,000.00 | 26,306,000.00 |
Expense From Sharebased Payment Transactions With Employees | 2,283,000.00 | 3,773,000.00 |
Profit Loss From Operating Activities | -18,989,000.00 | -16,625,000.00 |
Finance Income | 31,000.00 | 267,000.00 |
Finance Costs | 288,000.00 | 856,000.00 |
Profit Loss Before Tax | -19,246,000.00 | -17,213,000.00 |
Income Tax Expense Continuing Operations | -2,692,000.00 | -364,000.00 |
Profit (loss) | -16,555,000.00 | -16,850,000.00 |
Profit Loss Attributable To Owners Of Parent | -16,555,000.00 | -16,850,000.00 |
Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
---|---|---|---|
Profit (loss) | N/A | -16,555,000.00 | -16,850,000.00 |
Adjustments For Income Tax Expense | N/A | -2,692,000.00 | -364,000.00 |
Adjustments For Increase Decrease In Trade Account Payable | N/A | N/A | 679,000.00 |
Adjustments For Depreciation And Amortisation Expense | N/A | 273,000.00 | 1,970,000.00 |
Adjustments For Provisions | N/A | 0.00 | 289,000.00 |
Adjustments For Sharebased Payments | N/A | 1,787,000.00 | 2,944,000.00 |
Cash Flows From Used In Operations | N/A | -16,306,000.00 | -10,612,000.00 |
Income Taxes Paid Refund Classified As Operating Activities | N/A | 50,000.00 | 0.00 |
Cash Flows From Used In Operating Activities | N/A | -19,550,000.00 | -9,919,000.00 |
Cash Flows From Used In Investing Activities | N/A | -504,000.00 | -827,000.00 |
Proceeds From Issuing Shares | N/A | 18,630,000.00 | 265,000.00 |
Proceeds From Borrowings Classified As Financing Activities | N/A | 6,960,000.00 | 15,281,000.00 |
Repayments Of Borrowings Classified As Financing Activities | N/A | 325,000.00 | 40,000.00 |
Payments Of Lease Liabilities Classified As Financing Activities | N/A | 482,000.00 | 549,000.00 |
Cash Flows From Used In Financing Activities | N/A | 23,580,000.00 | 14,957,000.00 |
Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | 0.00 |
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 3,526,000.00 | 4,211,000.00 |
Cash and cash equivalents | 25,842,000.00 | 29,368,000.00 | 33,579,000.00 |
Please note that some sums might not add up.
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
19.06.2024 | None | Other | Other | EUR 35,700.00 |
17.06.2024 | None | Other | Other | EUR 35,800.00 |
17.06.2024 | None | Other | Other | EUR 35,700.00 |
13.06.2024 | None | Other | Sell | EUR 45,879.09 |
03.06.2024 | None | Other | Sell | EUR 314,512.00 |
FR0012127173
969500HIUWVGY6NZSM05
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.